BeOne Medicines AG (ONC)
NASDAQ: ONC · Real-Time Price · USD
298.16
-0.74 (-0.25%)
At close: Apr 28, 2026, 4:00 PM EDT
298.50
+0.34 (0.11%)
After-hours: Apr 28, 2026, 6:02 PM EDT
BeOne Medicines AG Stock Forecast
Stock Price Forecast
The 11 analysts with 12-month price forecasts for BeOne Medicines AG stock have an average target of 380.45, with a low estimate of 290 and a high estimate of 425. The average target predicts an increase of 27.60% from the current stock price of 298.16.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 27, 2026.
Analyst Ratings
The average analyst rating for BeOne Medicines AG stock from 11 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 8 | 8 | 8 | 8 | 7 | 6 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 12 | 12 | 12 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wolfe Research | Wolfe Research | Buy Initiates $340 | Buy | Initiates | $340 | +14.03% | Mar 27, 2026 |
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $420 → $290 | Strong Buy → Hold | Downgrades | $420 → $290 | -2.74% | Mar 16, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $417 → $425 | Buy | Maintains | $417 → $425 | +42.54% | Feb 27, 2026 |
| Truist Securities | Truist Securities | Strong Buy Maintains $400 → $412 | Strong Buy | Maintains | $400 → $412 | +38.18% | Feb 27, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $400 → $410 | Strong Buy | Maintains | $400 → $410 | +37.51% | Feb 27, 2026 |
Financial Forecast
Revenue This Year
45.27B
from 5.34B
Increased by 747.23%
Revenue Next Year
52.41B
from 45.27B
Increased by 15.78%
EPS This Year
3.30
from 2.47
Increased by 33.64%
EPS Next Year
4.86
from 3.30
Increased by 47.12%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 48.6B | 59.8B | ||||||
| Avg | 45.3B | 52.4B | ||||||
| Low | 42.0B | 46.6B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 809.5% | 32.2% | ||||||
| Avg | 747.2% | 15.8% | ||||||
| Low | 686.5% | 3.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 3.84 | 7.07 | ||||||
| Avg | 3.30 | 4.86 | ||||||
| Low | 2.90 | 2.93 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 55.6% | 114.1% | ||||||
| Avg | 33.6% | 47.1% | ||||||
| Low | 17.4% | -11.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.